Chiesi Farmaceutici SpA develops and markets pharmaceutical products. The firm specializes in research, development and production of drugs in respiratory dosage forms, such as metered-dose inhalers and sterile unit dose vials. The company was founded by Giacomo Chiesi in 1935 and is headquartered in Parma, Italy.

The Medicines Company is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. The Company markets Angiomax(R) (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, and Cleviprex(R) (clevidipine butyrate) injectable emulsion in the United States for the reduction of blood pressure when oral therapy is not feasible or not desirable. The Company also has two products in late stage development: cangrelor, an investigational antiplatelet agent, and oritavancin, a semi-synthetic lipoglycopeptide antibiotic. The Company's pipeline also includes a serine protease inhibitor, CU2010, in early-stage development.

Olon is one of the largest European developers and manufacturers, supplying APIs for the pharmaceutical industry worldwide both, for Generic as well as for contract manufacturing. OLON owns 5 manufacturing sites in northern Italy (Rodano, Settimo Torinese, Garbagnate Milanese, Mulazzano and Dorno) with more than 800 employees while INFA Group, with more than 400 employees, has 2 manufacturing sites in Italy, Labochim and Sifavitor, and 1 in Spain, Derivados Químicos.

Yabao Pharmaceutical Group Co., Ltd. engages in the development, production, and sale of pharmaceutical products. It focuses on medicine and health business. The company's products include Chinese and western medicine preparations, raw materials, and pharmaceutical packaging materials, mainly for the elderly chronic drug and women and children medication; cardiovascular and cerebrovascular drugs, and health products. It also involves in the cultivation of Chinese herbal medicines. Yabao Pharmaceutical Group was founded on January 26, 1999 and is headquartered in Beijing. China.

Yancheng Jinming Pharmaceutical Co., Ltd., established on 2015-01-14, Business scope includes pharmaceutical intermediates,API,Medical device research and development,technology transfer;medicine,Testing technical services for chemical products;Design of pharmaceutical and chemical equipment,install service;Chemical Products(Excluding hazardous chemicals),Class I medical device,Instrument and equipment sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

China State Institute of Pharmaceutical Industry is a Chinese company located in Shanghai and ultimately controlled by the Government of China. The firm regulates pharmaceutical companies.

ScinoPharm Taiwan Ltd. engages in the research, development, manufacturing, and sales of active pharmaceutical ingredients and injections. It also provides consulting and biotechnology services. The company's products include abiraterone acetate, anastrozole, apixaban, apremilast, atazanavir sulfate, azacitidine, benazepril hydrochloride, bortezomib, capecitabine, celecoxib, cladribine, dantrolene sodium, decitabine, desmopressin acetate, docetaxel anhydrous, docetaxel trihydrate, entecavir, enzalutamide, exemestane, flumazenil, fulvestrant, galantamine, gefitinib, gemcitabine hydrochloride, ondansetron hydrochloride, and paclitaxel. ScinoPharm Taiwan was founded on November 11, 1997 and is headquartered in Tainan, Taiwan.

Part of Sino Biopharmaceutical Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (doing business as Chia Tai-Tianqing Pharmaceutical Co Ltd) is a company headquartered in Lianyungang, China. The firm manufactures pharmaceutical products. It was founded in 1969. Kang Xin Yu is the current CEO of the firm.

hejiang Yongning Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is a pharmaceutical enterprise mainly engaged in R&D and production of innovative medicines and preparations. It is a national high-tech enterprise, an innovative pilot enterprise and a patent demonstration enterprise in Zhejiang Province.

Jiangsu Hengrui Pharmaceuticals Co., Ltd. engages in the research, development, manufacture, and sale of drugs. It specializes in antineoplastic agents, surgical anesthesia drugs, features infusion, contrast agents, and cardiovascular drugs. The firm’s products include tablets, oral solution, and suspension of antineoplastic drugs and narcotic drugs; psychotropic substances; soft capsules; freeze-dried powder injection; powder injection; high-volume injection, including multi-layer co-extruded infusion bag, with anti-tumor drugs; small volume injections, including antineoplastic drugs, psychotropic drugs, and non-final sterilization; biological engineering products such as polyethylene glycol recombinant human granulocyte stimulating factor injection; hard capsules; granules; powder; and film and gel. The company was founded in 1970 and is headquartered in Lianyungang, China.

Part of Jiangsu Hengrui Pharmaceuticals Co., Ltd., Chengdu Suncadia Pharmaceuticals Co., Ltd. is a Chinese company located in Chengdu. The firm engages in research and development of generic drugs.

Eli Lilly engages in the discovery, development, manufacture, and sale of products in the pharmaceutical products business segment. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico, and 25 other countries. Its products are sold in approximately 135 countries. It also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.

BociMed is a company engaged in drug research and development and clinical research. Through the establishment of a standardized service system, it provides high-quality R&D and outsourcing services for drug discovery, preclinical pharmaceutical research and development, clinical I-IV trials and registration.Shanghai Bozhiyan New Drug Technology Co., Ltd. is a high-tech enterprise specializing in drug research and development technical services, Shanghai High-tech Enterprise, Shanghai Credit Creation Enterprise, and Shanghai Small and Medium Enterprise Innovation Undertaking Enterprise. The company started in 2007 and was formerly known as Shanghai Maibo Pharmaceutical Technology Co., Ltd., registered in Jinshan Petrochemical Zone, mainly engaged in raw material sales, drug import registration and regional cooperation development in China. In 2012,

Part of CSPC Pharmaceutical Group Ltd., CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co., Ltd. is a company headquartered in China. The firm engages in pharmaceutical research and development.

Yihe (Huzhou) Biomedical Technology Co., Ltd., established on 2019-12-12, The scope of business includes engaging in biotechnology,Technical consulting in the field of pharmaceutical product technology,technology transfer,technology development,Technical Services,Chemical products and raw materials(Removal of hazardous chemicals,Monitor Chemicals,civilian explosives,precursor chemicals)promotion of,one,Class II medical device operation,Business Consulting,Engaged in the import and export of goods and technology(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ.

Tianjin Hankang Pharmaceutical Biotechnology Co., Ltd. is a high-tech enterprise with independent intellectual property rights and specialized in R&D, production and sales of pharmaceuticals. In 2009, he was awarded the title of “Tianjin Enterprise Technology Center”. In 2013, he was included in the list of small giant growth companies that the mayor focused on. In 2014, Hankang R&D Center was named “Tianjin Key Laboratory of Enterprises”. 　　Hankang is mainly engaged in the research of new chemical drugs, and the technical sources are all independent research and development. The company has a professional research team, technicians are all undergraduate or above, and at the same time employ many well-known domestic and foreign experts as technical consultants, scientific research results are remarkable. At present, more than 180 products have been successfully developed, more than 40 new drug certificates, more than 90 clinical approvals for new drugs, and more than 40 production approvals. He applied for more than 140 invention patents and obtained more than 60 invention patent certificates. He was awarded Tianjin Tianjin Invention Patent Pilot Enterprise twice.

AstraZeneca has always believed in science, inspires infinite possibilities, and puts science at the top of all work. AstraZeneca's strategically important core treatment areas, and are committed to exploring pathogenic mechanisms, treatment methods, and innovative drugs, so that science can change people's lives and bring it to the medical industry Significant changes.

Shandong Bainuo Pharmaceutical Co., Ltd., established on 2000-08-02, Business scope includes drug research and development,Technology transfer and related technical consultation;pharmaceutical production,Sales;Import and export of goods and technology(Except for the import and export of goods and technologies that are prohibited by the state or involve administrative approval).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Nantong Hongci Pharmaceutical Co., Ltd., established on 2003-04-03, Business scope includes production and sales of raw materials,Research and development of new drugs,modified starch,Food additive production,Processing and sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments) General project:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)